Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
PhotoCure |
---|---|
Information provided by: | PhotoCure |
ClinicalTrials.gov Identifier: | NCT00833183 |
A study of safety and efficacy of topical methyaminlevulinate 80mg/g with and without occlusion followed by red light exposure in subjects with facial acne.
Condition | Intervention | Phase |
---|---|---|
Acne |
Drug: MAL |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Single Blind (Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | A Study of Safety and Efficacy of Topical Methylaminolevulinate 80mg/g With and Without Occlusion Followed by Red Light Exposure in Subjects With Facial Acne |
Enrollment: | 44 |
Study Start Date: | July 2007 |
Study Completion Date: | July 2008 |
Primary Completion Date: | July 2008 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
25 J/cm2, with occlusion on right side: Active Comparator
Subjects will receive MAL cream in a thin layer on both sides of the face (except nose and peri-ocular area) at a concentration of 80 mg/g). Occlusion will be applied to one half of the face. After an incubation time of 90 minutes both sides of the face will be exposed to either 25 J/cm2 of red light starting with the occluded side first.
|
Drug: MAL
80 mg/g cream one administration with incubation for 90 minutes
|
37 J/cm2, with occlusion on right side: Active Comparator
Subjects will receive MAL cream in a thin layer on both sides of the face (except nose and peri-ocular area) at a concentration of 80 mg/g). Occlusion will be applied to one half of the face. After an incubation time of 90 minutes both sides of the face will be exposed to 37 J/cm2 of red light starting with the occluded side first.
|
Drug: MAL
80 mg/g cream one administration with incubation for 90 minutes
|
25 J/cm2 , with occlusion on left side: Active Comparator
Subjects will receive MAL cream in a thin layer on both sides of the face (except nose and peri-ocular area) at a concentration of 80 mg/g). Occlusion will be applied to one half of the face. After an incubation time of 90 minutes both sides of the face will be exposed to either 25 J/cm2 of red light starting with the occluded side first.
|
Drug: MAL
80 mg/g cream one administration with incubation for 90 minutes
|
37 J/cm2 , with occlusion on left side: Active Comparator
Subjects will receive MAL cream in a thin layer on both sides of the face (except nose and peri-ocular area) at a concentration of 80 mg/g). Occlusion will be applied to one half of the face. After an incubation time of 90 minutes both sides of the face will be exposed to 37 J/cm2 of red light starting with the occluded side first.
|
Drug: MAL
80 mg/g cream one administration with incubation for 90 minutes
|
Photocure ASA has developed a cream formulation containing methyl aminolevulinate (MAL), an ester of ALA. There is extensive experience with the safety of MAL-PDT in humans.
This study will assess safety and efficacy of four treatments with methylaminolevulinate (MAL) at 80 mg/g performed with and without occlusion and followed by red light exposure 90 minutes later in subjects with facial acne vulgaris. Subjects will be randomized to one of two groups of 20 subjects: Group 1 will receive 25 J/cm2 of red light (45 mW/cm2) and group 2 will receive 37 J/cm2 of red light (90 mW/cm2). For each subject one side of the face will be randomized to receive MAL for 90 minutes without occlusion and the other side of the face will receive MAL for 90 minutes with occlusion.
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Canada, Quebec | |
Innovaderm Research Inc. | |
Montreal, Quebec, Canada, H2K 4L5 | |
Innovaderm Research Inc | |
Laval, Quebec, Canada, H7S 2C6 |
Principal Investigator: | Robert Bissonnette, MD MSC FRCPC | Innovaderm Research Inc. |
Responsible Party: | Photocure ( Per Fuglerud ) |
Study ID Numbers: | INNO-6005 |
Study First Received: | January 29, 2009 |
Last Updated: | January 29, 2009 |
ClinicalTrials.gov Identifier: | NCT00833183 History of Changes |
Health Authority: | Canada: Health Canada |
Exanthema Facial Dermatoses Skin Diseases |
Facies Sebaceous Gland Diseases Acne Vulgaris |
Facial Dermatoses Skin Diseases Acneiform Eruptions Sebaceous Gland Diseases Acne Vulgaris |